Consultant to conduct the systematic review and budget impact analysis of TB drug which is proposed to include into the SHI package

Call for consultancy

1.About FHI 360

FHI 360 is a nonprofit organization that mobilizes research, resources and relationships so that people everywhere can access the opportunities they need to lead full, healthy lives. FHI 360 serves more than 70 countries and all U.S. states and territories.

2. Detailed Description of Tasks to be Performed:

FHI 360 is currently implementing programs to address challenges in HIV prevention, testing, and treatment, Tuberculosis (TB) case finding and treatment, anti-microbial resistance, health system strengthening, maternal and child health and nutrition, and global health security.

With aims to ensure the financial sustainability of essential drugs for TB treatment in Vietnam, FHI 360 is seeking a qualified and motivated Vietnamese candidate to provide a consultancy service in supporting the TB treatment program to include its essential drug into the Social Health Insurance (SHI) package.

3. Objectives

The consultancy service aims to provide support to the National TB Program (NTP) to with key evidence to facilitate the roadmap of registering the second line TB drug for TB drug resistance treatment, pretonamid (Pa), into the SHI package, following updated MOH regulations and guidance, including but not limited to:

Conduct the systematic review on cost effectiveness analysis (CEA) of the selected TB drugs for TB drug resistance treatment – (Pretomanid)
Conduct the budget impact analysis (BIA) of pretomanid for TB drug resistance treatment, in close collaboration with NTP.
Develop an executive summary of the above reports which cover the key findings of the two reports.

4. Scope of work and expected deliverables:

The qualified consultant will conduct the following tasks:

Participate in meetings with NTP, key relevant stakeholders and SET/FHI team to define assessment needs.
Develop the consultant inception plan to perform the assigned tasks with timeline.
Conduct the systematic review on the CEA of pretomanid and develop findings report, following MOH updated guidance at Decision 1315/QĐ-BYT dated 17 May 2024.
Collect data and analyze the data collected to develop the BIA findings report, following MOH updated guidance at Decision 1315/QĐ-BYT dated 17 May 2024.
Present findings and update the reports based on feedback from NTP, FHI team and key relevant stakeholders.
Develop a summary report of CEA report and BIA report and revise it based on comments from stakeholders.
Provide a final consultant report in both Vietnamese and English.
Other relevant tasks as needed.

The Table below summarizes expected deliverables and timelines:

Deliverables	Estimate LOE (days)	Due date
Meeting(s) to discuss objectives and expectations and develop data collection tools	2	25 March 2026
Draft report on systematic review of CEA of pretomanid	15	20 May 2026
Draft report on budget impact analysis of pretomanid for resistance TB treatment	18	20 May 2026
Finalized reports based on comments	10	5 June 2026
A summary of systematic review and budget impact analysis	5	10 June 2026
Total LOE	50

5. Required qualifications

Advanced degree in public health, health sciences, pharmaceutical sciences, or related fields.
Strong knowledge and experience in eco‑pharmaceutical analysis Experience conducting CEA/BIA studies
Understanding of the needs of TB treatment
Experience in working with international organizations
High degree of self-motivation, ability to work independently with tight deadlines
Excellent communication and interpersonal skills; ability to interact with external and internal audiences of various types and levels; Spoken and written fluency required in English and Vietnamese

6. Evaluation Criteria

Applications will be evaluated based on the applicant’s experience and qualifications as detailed above.

7. Required Documentation

Proposals must include the following components:

Applicants’ CV and highest-level degree
Cover letter explaining relevant experience in pharmaceutical science, conducting eco-pharmaceutical studies, working with government officials, operating under international donor regulations, and language skills
Proposed daily rate
FHI 360 Biodata form

8. Application

Application to this call should be submitted by email to [email protected] no later than 5PM, March 9, 2026 with the subject line “SET-Consultant-Systematic review and budget impact analysis”
All prospective vendors must comply with the safeguarding policiesof our organization. Any violations of the policies may result in immediate contract termination without liability for the organization.
Only shortlisted applicants will be contacted.

9. FHI 360 Disclaimers 

FHI 360 may perform a background check on any selected vendor.
FHI 360 may cancel the solicitation and not award.
FHI 360 may reject any or all responses received.
Issuance of the solicitation does not constitute an award commitment by FHI 360.
FHI 360 reserves the right to disqualify any offer based on failure of the offeror to follow solicitation instructions.
FHI 360 will not compensate any offeror for responding to solicitation.
FHI 360 reserves the right to issue an award based on initial evaluation of offers without further discussion.
FHI 360 may choose to award only part of the activities in the solicitation, or issue multiple awards based on the solicitation activities.
FHI 360 has the right to issue amendments to the RFQ at any time.